TOP TIERMARKET NEWSWIRE

News & sentiment

EXELIXIS INC (EXEL) — News & AI sentiment

EXELIXIS INC (EXEL) news roundup. 2 stories in the past week, 9 over 30 days. Average 30-day sentiment is 56.8/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 1 sales totalling $527K — net selling of $527K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

2

avg sentiment 68.5/100

30d stories

9

avg sentiment 56.8/100

Insider net (90d)

$527K

0 buys · 1 sells

Congress (90d)

0

0 buys · 0 sells

EXEL news in the last 24 hours, 7 days, 30 days and 90 days

How much EXEL coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	EXEL stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	2	68.5/100	EXEL headlines →
Last 30 days	9	56.8/100	EXEL headlines →
Last 90 days	66	50.2/100	EXEL headlines →

Latest stories on EXEL

Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock

MarketBeat74 · bullishproduct/pr

2d ago

Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy

The Motley Fool63 · neutralanalyst

4d ago

Exelixis price target raised to $65 from $55 at Citizens

The Fly64 · neutralanalyst

Oct 19

Citizens raises Exelixis stock price target to $65 on ESMO data

Investing.com Analyst Ratings64 · neutralanalyst

Oct 19

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

StockTitan50 · neutralgeneral

Oct 15

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

PR Newswire34 · bearishgeneral

Oct 13

Exelixis price target raised to $51 from $45 at RBC Capital

The Fly63 · neutralanalyst

Oct 9

Exelixis price target lowered to $45 from $46 at RBC Capital

The Fly38 · neutralanalyst

Oct 8

Exelixis price target raised to $54 from $52 at Truist

The Fly61 · neutralanalyst

Oct 7

Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha56 · neutralgeneral

Sep 15

Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle

Yahoo Finance58 · neutralproduct/pr

Sep 15

Citizens reiterates Exelixis stock rating on FDA review extension

Investing.com Analyst Ratings55 · neutralanalyst

Sep 14

Exelixis: Why The 3-Month Delay Is More Negative Than It May Seem (Downgrade)

Seeking Alpha34 · bearishanalyst

Sep 14

Exelixis: The FDA Delay Costs Less Than The Market Thinks

Seeking Alpha48 · neutralgeneral

Sep 14

Analysts’ Opinions Are Mixed on These NA Stocks: SpaceX (SPCX), Insmed (INSM) and Exelixis (EXEL)

Business Insider50 · neutralanalyst

Sep 12

EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term

Stocktwits News34 · bearishgeneral

Sep 11

Exelixis risk of rejection ‘low’ despite zanzalintinib delay, says William Blair

The Fly58 · neutralgeneral

Sep 11

Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay

Investors.com32 · bearishgeneral

Sep 11

Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months

InvestorsHub34 · bearishgeneral

Sep 11

Exelixis zanzalintinib NDA review extended three months by FDA

Seeking Alpha38 · neutralgeneral

Sep 11

Exelixis stock falls as FDA extends zanzalintinib review

Investing.com Markets34 · bearishgeneral

Sep 11

Exelixis: FDA Extends Review of Zanzalintinib in Combination With Atezolizumab for Metastatic Colorectal Cancer >EXEL

MarketWatch53 · neutralgeneral

Sep 11

FDA Extends Review Timeline for Exelixis Cancer Drug

TipRanks34 · bearishproduct/pr

Sep 11

Exelixis says FDA extends review period for zanzalintinib NDA by three months

The Fly34 · bearishgeneral

Sep 11

EXELIXIS, INC. (EXEL) files 8-K

SEC 8-K50 · neutralgeneral

Sep 11

Open EXEL in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →